Trump to Sign Executive Order on Ibogaine Research for PTSD
The Trump administration is preparing to sign an executive order aimed at facilitating federal research into ibogaine, a psychedelic drug used internationally to treat post-traumatic stress disorder (PTSD), addiction, and depression. Although ibogaine will remain a Schedule I controlled substance in the United States, the order seeks to open pathways for federal funding to evaluate its safety and efficacy, particularly for veterans suffering from PTSD and traumatic brain injuries. Currently, many Americans travel to unregulated clinics in Mexico and the Caribbean to access the treatment, which carries significant cardiac risks. The initiative follows state-level efforts, such as Texas allocating $50 million for similar research. While preliminary studies suggest potential benefits when combined with heart-protective measures like magnesium, scientific evidence remains limited to small observational trials. The administration aims to determine whether ibogaine is a legitimate medical treatment or ineffective, addressing the lack of standardized oversight in international clinics where adverse events, including fatalities, have been reported.
Wire timeline
Trump to Sign Executive Order on Ibogaine Research for PTSD
The Trump administration is preparing to sign an executive order aimed at facilitating federal research into ibogaine, a psychedelic drug used internationally to treat post-traumatic stress disorder (PTSD), addiction, and depression. Although ibogaine will remain a Schedule I controlled substance in the United States, the order seeks to open pathways for federal funding to evaluate its safety and efficacy, particularly for veterans suffering from PTSD and traumatic brain injuries. Currently, many Americans travel to unregulated clinics in Mexico and the Caribbean to access the treatment, which carries significant cardiac risks. The initiative follows state-level efforts, such as Texas allocating $50 million for similar research. While preliminary studies suggest potential benefits when combined with heart-protective measures like magnesium, scientific evidence remains limited to small observational trials. The administration aims to determine whether ibogaine is a legitimate medical treatment or ineffective, addressing the lack of standardized oversight in international clinics where adverse events, including fatalities, have been reported.
Home - CBSNews.com